Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF
An observational, descriptive and cross-sectional study in a first moment, and cohort analytic in a second time, of 95 patients with non - small cell lung cancer in advanced stages, assisted at “Saturnino Lora Torres” Teaching Clinical Surgical Provincial Hospital and in 4 polyclinics of Santiago...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Centro Provincial de Información de Ciencias Médicas
2016-02-01
|
| Series: | Medisan |
| Subjects: | |
| Online Access: | http://medisan.sld.cu/index.php/san/article/view/737 |
| _version_ | 1818413393507254272 |
|---|---|
| author | Carlos Oliver Cobián Caballero Soraida Cándida Acosta Brooks Francisco Martínez Feria Lázaro Ibrahim Romero García |
| author_facet | Carlos Oliver Cobián Caballero Soraida Cándida Acosta Brooks Francisco Martínez Feria Lázaro Ibrahim Romero García |
| author_sort | Carlos Oliver Cobián Caballero |
| collection | DOAJ |
| description | An observational, descriptive and cross-sectional study in a first moment, and cohort analytic in a second time, of 95 patients with non - small cell lung cancer in advanced stages, assisted at “Saturnino Lora Torres” Teaching Clinical Surgical Provincial Hospital and in 4 polyclinics of Santiago de Cuba, was carried out during the period 2006-2013, in order to estimate the survival in them after the vaccination with CIMAvax-EGF and to identify the factors associated to the mortality, for which Kaplan-Meier method and Cox regression were used, respectively. The global survival in 2 years was 20.7%, with a median of 13 months, as long as the survival a year after applying the vaccine was 36.5%. On the other hand, in the stage IIIB, the favorable response to the first line treatment, the chemotherapy-radiotherapy-vaccine combination and the immunization in 4 or more occasions, facilitated a significantly higher survival. The unfavorable reaction to the first therapeutic line constituted a prediction factor of death risk increase in the population affected. |
| first_indexed | 2024-12-14T11:02:29Z |
| format | Article |
| id | doaj.art-448adea5fedc4c949547a090526c3516 |
| institution | Directory Open Access Journal |
| issn | 1029-3019 |
| language | Spanish |
| last_indexed | 2024-12-14T11:02:29Z |
| publishDate | 2016-02-01 |
| publisher | Centro Provincial de Información de Ciencias Médicas |
| record_format | Article |
| series | Medisan |
| spelling | doaj.art-448adea5fedc4c949547a090526c35162022-12-21T23:04:40ZspaCentro Provincial de Información de Ciencias MédicasMedisan1029-30192016-02-01203251Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGFCarlos Oliver Cobián Caballero0Soraida Cándida Acosta Brooks1Francisco Martínez Feria2Lázaro Ibrahim Romero García3Hospital Provincial Docente Clinicoquirúrgico “Saturnino Lora Torres”, Universidad de Ciencias Médicas, Santiago de CubaHospital Provincial Docente Clinicoquirúrgico “Saturnino Lora Torres”, Universidad de Ciencias Médicas, Santiago de CubaHospital General "Juan Bruno Zayas A."Hospital Provincial Docente Clinicoquirúrgico “Saturnino Lora Torres”, Universidad de Ciencias Médicas, Santiago de CubaAn observational, descriptive and cross-sectional study in a first moment, and cohort analytic in a second time, of 95 patients with non - small cell lung cancer in advanced stages, assisted at “Saturnino Lora Torres” Teaching Clinical Surgical Provincial Hospital and in 4 polyclinics of Santiago de Cuba, was carried out during the period 2006-2013, in order to estimate the survival in them after the vaccination with CIMAvax-EGF and to identify the factors associated to the mortality, for which Kaplan-Meier method and Cox regression were used, respectively. The global survival in 2 years was 20.7%, with a median of 13 months, as long as the survival a year after applying the vaccine was 36.5%. On the other hand, in the stage IIIB, the favorable response to the first line treatment, the chemotherapy-radiotherapy-vaccine combination and the immunization in 4 or more occasions, facilitated a significantly higher survival. The unfavorable reaction to the first therapeutic line constituted a prediction factor of death risk increase in the population affected.http://medisan.sld.cu/index.php/san/article/view/737supervivencia global, cáncer de pulmón de células no pequeñas, vacuna contra el cáncer, cimavax-egf. |
| spellingShingle | Carlos Oliver Cobián Caballero Soraida Cándida Acosta Brooks Francisco Martínez Feria Lázaro Ibrahim Romero García Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF Medisan supervivencia global, cáncer de pulmón de células no pequeñas, vacuna contra el cáncer, cimavax-egf. |
| title | Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF |
| title_full | Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF |
| title_fullStr | Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF |
| title_full_unstemmed | Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF |
| title_short | Survival in patients with non - small cell lung cancer vaccinated with CIMAvax-EGF |
| title_sort | survival in patients with non small cell lung cancer vaccinated with cimavax egf |
| topic | supervivencia global, cáncer de pulmón de células no pequeñas, vacuna contra el cáncer, cimavax-egf. |
| url | http://medisan.sld.cu/index.php/san/article/view/737 |
| work_keys_str_mv | AT carlosolivercobiancaballero survivalinpatientswithnonsmallcelllungcancervaccinatedwithcimavaxegf AT soraidacandidaacostabrooks survivalinpatientswithnonsmallcelllungcancervaccinatedwithcimavaxegf AT franciscomartinezferia survivalinpatientswithnonsmallcelllungcancervaccinatedwithcimavaxegf AT lazaroibrahimromerogarcia survivalinpatientswithnonsmallcelllungcancervaccinatedwithcimavaxegf |